$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| UPDATE ON CAPITELLO-290 PHASE III TRIAL | 18 Jun 2024 |
| IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | 17 Jun 2024 |
| DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2024 |
| FORM 6-K | 04 Jun 2024 |
| BLOCK LISTING INTERIM REVIEW | 03 Jun 2024 |
| TOTAL VOTING RIGHTS | 03 Jun 2024 |
| TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | 03 Jun 2024 |
| DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | 28 May 2024 |
| ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | 21 May 2024 |
| ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | 20 May 2024 |
| SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | 16 May 2024 |
| DIRECTOR/PDMR SHAREHOLDING | 15 May 2024 |
| ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | 07 May 2024 |
| CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | 02 May 2024 |
| TOTAL VOTING RIGHTS | 01 May 2024 |
| TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | 29 Apr 2024 |
| ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW | 29 Apr 2024 |
| 1ST QUARTER RESULTS | 25 Apr 2024 |
| RESULT OF AGM | 11 Apr 2024 |
| ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% | 11 Apr 2024 |
